Nautilus Biotechnology Stock Investor Sentiment

NAUT Stock  USD 1.43  0.04  2.72%   
Slightly above 61% of Nautilus Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that many traders are alarmed. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
  
over six months ago at insidermonkey.com         
Nautilus Biotechnology, Inc. Q1 2024 Earnings Call Transcript
insidermonkey News
over six months ago at gurufocus.com         
Nautilus Biotechnology Inc Q1 2024 Earnings Call Transcript Highlights A Detailed ...
Gurufocus Stories at Macroaxis
over six months ago at finance.yahoo.com         
Nautilus Biotechnology, Inc. Q1 2024 Earnings Call Transcript
Yahoo News
over six months ago at globenewswire.com         
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
over six months ago at gurufocus.com         
Nautilus Biotechnology Inc Q1 2024 Earnings Narrower Loss Than Expected
Gurufocus Stories at Macroaxis
over six months ago at investorplace.com         
NAUT Stock Earnings Nautilus Biotechnology Beats EPS for Q1 2024
sbwire news
over six months ago at seekingalpha.com         
Nautilus Biotechnology GAAP EPS of -0.15 beats by 0.01
seekingalpha News
over six months ago at news.google.com         
Nautilus Biotechnology Scheduled to Post Quarterly Earnings on Tuesday - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Jeff Bezos Earns So Much He Could Buy a Rolex Every Second How Does He Make Money?
Yahoo News
over six months ago at finance.yahoo.com         
Disposition of 3647500 shares by Altman Michael Seth of Nautilus Biotechnology subject to Rule 16b-3
Yahoo News
over six months ago at news.google.com         
Nautilus Biotechnology Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Mcilwain Matthew S of 13568 shares of Nautilus Biotechnology at 7.6849 subject to Rul...
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Subra Sankar of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
Macroaxis News
over six months ago at globenewswire.com         
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
Macroaxis News: globenewswire.com
over six months ago at www.macroaxis.com         
Acquisition by Posard Matthew L. of 86467 shares of Nautilus Biotechnology at 2.7 subject to Rule 16...
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. That information is available publicly through Nautilus media outlets and privately through word of mouth or via Nautilus internal channels. However, regardless of the origin, that massive amount of Nautilus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.

Nautilus Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.